Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Editorial

Denosumab cessation

Chad L. Deal, MD
Cleveland Clinic Journal of Medicine June 2020, 87 (6) 339-341; DOI: https://doi.org/10.3949/ccjm.87a.20040
Chad L. Deal
Department of Rheumatic and Immunologic Disease, Center for Osteoporosis and Metabolic Bone Diseases, Orthopedic and Rheumatologic Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 87 no. 6 339-341
DOI 
https://doi.org/10.3949/ccjm.87a.20040
PubMed 
32487553

Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online June 2, 2020.

Copyright & Usage 
Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Chad L. Deal, MD⇑
  1. Department of Rheumatic and Immunologic Disease, Center for Osteoporosis and Metabolic Bone Diseases, Orthopedic and Rheumatologic Institute, Cleveland Clinic
  1. Address: Chad L. Deal, MD, Department of Rheumatic and Immunologic Disease, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; dealc{at}ccf.org
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 87 (6)
Cleveland Clinic Journal of Medicine
Vol. 87, Issue 6
1 Jun 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Denosumab cessation
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
Please verify that you are a real person.
Citation Tools
Denosumab cessation
Chad L. Deal
Cleveland Clinic Journal of Medicine Jun 2020, 87 (6) 339-341; DOI: 10.3949/ccjm.87a.20040

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Denosumab cessation
Chad L. Deal
Cleveland Clinic Journal of Medicine Jun 2020, 87 (6) 339-341; DOI: 10.3949/ccjm.87a.20040
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget

Jump to section

  • Article
    • RAPID BONE LOSS AFTER DENOSUMAB IS STOPPED
    • MULTIPLE VERTEBRAL FRACTURES
    • IF DENOSUMAB MUST BE STOPPED
    • CONSIDERATIONS DURING THE COVID-19 PANDEMIC
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • Vertebral fractures after denosumab cessation
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Nitrogen: The unsung hero of vascular physiology
  • The beat goes on: Highlights from the new American and European A-fib guidelines
  • Subclinical hypothyroidism: What’s in a name?
Show more Editorial

Similar Articles

Subjects

  • Drug Therapy
  • Endocrinology
  • Geriatrics
  • Imaging
  • Pain
  • Women's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire